894 related articles for article (PubMed ID: 22102647)
1. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials.
Anthony K; Cirak S; Torelli S; Tasca G; Feng L; Arechavala-Gomeza V; Armaroli A; Guglieri M; Straathof CS; Verschuuren JJ; Aartsma-Rus A; Helderman-van den Enden P; Bushby K; Straub V; Sewry C; Ferlini A; Ricci E; Morgan JE; Muntoni F
Brain; 2011 Dec; 134(Pt 12):3547-59. PubMed ID: 22102647
[TBL] [Abstract][Full Text] [Related]
2. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping.
Anthony K; Arechavala-Gomeza V; Ricotti V; Torelli S; Feng L; Janghra N; Tasca G; Guglieri M; Barresi R; Armaroli A; Ferlini A; Bushby K; Straub V; Ricci E; Sewry C; Morgan J; Muntoni F
JAMA Neurol; 2014 Jan; 71(1):32-40. PubMed ID: 24217213
[TBL] [Abstract][Full Text] [Related]
3. Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients.
Helderman-van den Enden AT; Straathof CS; Aartsma-Rus A; den Dunnen JT; Verbist BM; Bakker E; Verschuuren JJ; Ginjaar HB
Neuromuscul Disord; 2010 Apr; 20(4):251-4. PubMed ID: 20153965
[TBL] [Abstract][Full Text] [Related]
4. Deletion of Dystrophin In-Frame Exon 5 Leads to a Severe Phenotype: Guidance for Exon Skipping Strategies.
Toh ZY; Thandar Aung-Htut M; Pinniger G; Adams AM; Krishnaswarmy S; Wong BL; Fletcher S; Wilton SD
PLoS One; 2016; 11(1):e0145620. PubMed ID: 26745801
[TBL] [Abstract][Full Text] [Related]
5. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M
Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910
[TBL] [Abstract][Full Text] [Related]
6. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
[TBL] [Abstract][Full Text] [Related]
7. Causes of clinical variability in Duchenne and Becker muscular dystrophies and implications for exon skipping therapies.
Hoffman EP
Acta Myol; 2020 Dec; 39(4):179-186. PubMed ID: 33458572
[TBL] [Abstract][Full Text] [Related]
8. Exons 45-55 Skipping Using Antisense Oligonucleotides in Immortalized Human DMD Muscle Cells.
He M; Yokota T
Methods Mol Biol; 2023; 2640():313-325. PubMed ID: 36995604
[TBL] [Abstract][Full Text] [Related]
9. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
[TBL] [Abstract][Full Text] [Related]
10. The X-linked Becker muscular dystrophy (bmx) mouse models Becker muscular dystrophy via deletion of murine dystrophin exons 45-47.
Heier CR; McCormack NM; Tully CB; Novak JS; Newell-Stamper BL; Russell AJ; Fiorillo AA
J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):940-954. PubMed ID: 36628607
[TBL] [Abstract][Full Text] [Related]
11. Exon deletion patterns of the dystrophin gene in 82 Vietnamese Duchenne/Becker muscular dystrophy patients.
Tran VK; Ta VT; Vu DC; Nguyen ST; Do HN; Ta MH; Tran TH; Matsuo M
J Neurogenet; 2013 Dec; 27(4):170-5. PubMed ID: 24099565
[TBL] [Abstract][Full Text] [Related]
12. A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping.
Walmsley GL; Arechavala-Gomeza V; Fernandez-Fuente M; Burke MM; Nagel N; Holder A; Stanley R; Chandler K; Marks SL; Muntoni F; Shelton GD; Piercy RJ
PLoS One; 2010 Jan; 5(1):e8647. PubMed ID: 20072625
[TBL] [Abstract][Full Text] [Related]
13. Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy.
Cirak S; Feng L; Anthony K; Arechavala-Gomeza V; Torelli S; Sewry C; Morgan JE; Muntoni F
Mol Ther; 2012 Feb; 20(2):462-7. PubMed ID: 22086232
[TBL] [Abstract][Full Text] [Related]
14. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT
Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
[TBL] [Abstract][Full Text] [Related]
15. Large in-frame 5' deletions in DMD associated with mild Duchenne muscular dystrophy: Two case reports and a review of the literature.
Gibbs EM; Barthélémy F; Douine ED; Hardiman NC; Shieh PB; Khanlou N; Crosbie RH; Nelson SF; Miceli MC
Neuromuscul Disord; 2019 Nov; 29(11):863-873. PubMed ID: 31672265
[TBL] [Abstract][Full Text] [Related]
16. Morpholino Oligomer-Induced Dystrophin Isoforms to Map the Functional Domains in the Dystrophin Protein.
Li D; Adams AM; Johnsen RD; Fletcher S; Wilton SD
Mol Ther Nucleic Acids; 2020 Dec; 22():263-272. PubMed ID: 33230432
[TBL] [Abstract][Full Text] [Related]
17. The lack of the Celf2a splicing factor converts a Duchenne genotype into a Becker phenotype.
Martone J; Briganti F; Legnini I; Morlando M; Picillo E; Sthandier O; Politano L; Bozzoni I
Nat Commun; 2016 Jan; 7():10488. PubMed ID: 26796035
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model Neonates.
Lim KRQ; Echigoya Y; Nagata T; Kuraoka M; Kobayashi M; Aoki Y; Partridge T; Maruyama R; Takeda S; Yokota T
Mol Ther; 2019 Jan; 27(1):76-86. PubMed ID: 30448197
[TBL] [Abstract][Full Text] [Related]
19. Exons 45-55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene.
Echigoya Y; Lim KRQ; Melo D; Bao B; Trieu N; Mizobe Y; Maruyama R; Mamchaoui K; Tanihata J; Aoki Y; Takeda S; Mouly V; Duddy W; Yokota T
Mol Ther; 2019 Nov; 27(11):2005-2017. PubMed ID: 31416775
[TBL] [Abstract][Full Text] [Related]
20. The Future of Exon Skipping for Duchenne Muscular Dystrophy.
Aartsma-Rus A
Hum Gene Ther; 2023 May; 34(9-10):372-378. PubMed ID: 36924282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
